Zobrazeno 51 - 60
of 7 915
pro vyhledávání: ''
Autor:
Jürgen Steffgen, Steven J. Padula, Ulf Müller-Ladner, Christian Schwabe, Stefan Daniluk, Meera Ramanujam, Patrick Baum, Eva Dokoupilova, Herbert Kellner, Bernd Rosenstock, Rieke Alten, Brygida Kwiatkowska, Sudha Visvanathan, Rafał Ptaszyński, Anastasia G. Eleftheraki, Jay S. Fine, David Joseph, Richard Vinisko, Alena Petříková
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveTo evaluate the safety, efficacy and therapeutic mechanism of BI 655064, an antagonistic anti-CD40 monoclonal antibody, in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX-IR).MethodsIn total, 67 patien
Autor:
Dominique Baeten, Inka A. Fluri, Marleen G H van de Sande, Marc R. Kok, Arno W R van Kuijk, Henriëtte M. de Jong, Leonieke J J van Mens, Michael T. Nurmohamed
Publikováno v:
Annals of the rheumatic diseases, 78(5), 610-616. BMJ Publishing Group
van Mens, L J J, de Jong, H M, Fluri, I, Nurmohamed, M T, van de Sande, M G H, Kok, M, van Kuijk, A W R & Baeten, D 2019, ' Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: A double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate ', Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 610-616 . https://doi.org/10.1136/annrheumdis-2018-214746
Annals of the Rheumatic Diseases, 78(5), 610-616. BMJ Publishing Group
van Mens, L J J, de Jong, H M, Fluri, I, Nurmohamed, M T, van de Sande, M G H, Kok, M, van Kuijk, A W R & Baeten, D 2019, ' Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: A double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate ', Annals of the Rheumatic Diseases, vol. 78, no. 5, pp. 610-616 . https://doi.org/10.1136/annrheumdis-2018-214746
Annals of the Rheumatic Diseases, 78(5), 610-616. BMJ Publishing Group
ObjectivesEarly initiation of effective treatment favours remission in rheumatoid arthritis, but it remains unknown if the same concept applies to psoriatic arthritis (PsA). Therefore, this study investigated whether the combination of golimumab plus
Publikováno v:
Annals of the Rheumatic Diseases. 78:629-633
ObjectiveWe evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE).MethodsLLDAS attainment, discriminat
Autor:
Amr H. Sawalha, Shaylynn Miller, Patrick Coit, Pei-Suen Tsou, Nathan C Kilian, Mark Schonfeld, Dallas M Rohraff, Elizabeth Gensterblum-Miller, Paul Renauer
Publikováno v:
Annals of the Rheumatic Diseases. 78:519-528
ObjectiveWe examined genome-wide DNA methylation changes in CD8+ T cells from patients with lupus and controls and investigated the functional relevance of some of these changes in lupus.MethodsGenome-wide DNA methylation of lupus and age, sex and et
Autor:
Patrick Blanco, Pierre Duffau, Marie-Elise Truchetet, Christophe Richez, Marc Scherlinger, Estibaliz Lazaro, Julien Seneschal, Lionel Couzi, Claire Carcaud, Thomas Barnetche
Publikováno v:
Annals of the Rheumatic Diseases. 78:1007-1010
Many targeted therapies have been developed for systemic lupus erythematosus (SLE) in recent years and almost all have failed to meet their predesigned endpoints.1 Among these therapies, rituximab (RTX) has reported good results in several open-label
Autor:
Y Asukai, Robert L. Ohsfeldt, Sulabha Ramachandran, Ronald C Wielage, KA Kelton, Murray B. Urowitz
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesThe study (206347) compared organ damage progression in patients with systemic lupus erythematosus (SLE) who received belimumab in the BLISS long-term extension (LTE) study with propensity score (PS)-matched patients treated with standard o
Autor:
Michael A. Farrar, Lynn M. Heltemes-Harris, Gregory Hubbard, Can Hekim, Sean I. Tracy, Hrishi Venkatesh
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPhenotypic exhaustion of CD4+ T-cells is a strong negative prognostic factor in acute lymphoblastic leukemia (ALL).1–3 Despite this, PD1/PD-L1 immune checkpoint therapy has shown little activity in this disease setting to date. Factors in
Autor:
John-William Sidhom, Petra Ross-Macdonald, Megan Wind-Rotolo, Andrew Pardoll, Alexander Baras
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A872-A873
BackgroundCheckpoint inhibition (CPI) has changed the landscape of how oncologists treat advanced cancer 1–6; while there has been tremendous promise of immunotherapy, most patients do not respond to treatment.6 Biomarker development has grown as t
Autor:
Chun Chau Lawrence Cheung, Han Chong Toh, Yong Hock Justin Seah, Kiat Hon Lim, Su Pin Choo, Juntao Fang, Nicole Orpilla, Wai Meng David Tai, Justina Nadia Li Wen Lee, Joe Yeong
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune check-point blockade (ICB) is one of the emerging therapeutic options for advanced hepatocellular carcinoma (HCC). However, low response rates amongst patients necessitates the development of robust predictive biomarkers that identif
Autor:
Alvaro Padron, Tyler J. Curiel, Anand Kornepati, Myrna Garcia, Clare Murray, Yilun Deng, Haiyan Bai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTumor PD-L1 canonically signals to PD-1 on immune cells to evade immune destruction.1 We reported that tumor PD-L1 also mediates diverse pathologic intracellular signals,2 3 including promoting the ATM/Chk2 DNA damage response, and that gen